



Everest Medicines Limited
雲頂新耀有限公司
(incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號: 1952)

NOTIFICATION LETTER 通知信函

25 April 2024

Dear Non-registered holder^(Note),

Everest Medicines Limited (the “Company”)

- Notice of Publication of 2023 Annual Report and 2023 Environmental, Social and Governance Report (the “Current Corporate Communication”)

The English and Chinese versions of the Current Corporate Communication are available on the Company’s website at www.everestmedicines.com and are also available on the website of Hong Kong Exchanges and Clearing Limited (“HKEx”) at www.hkexnews.hk.

If you would like to receive the Current Corporate Communication and all future Corporate Communications[#] in printed form, please complete the Request Form on the reverse side of this letter and sign and return it by post or by hand to the Company c/o the Company’s share registrar in Hong Kong (the “**Hong Kong Share Registrar**”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong. If you post your reply in Hong Kong, you may use the mailing label in the Request Form and need not affix a stamp on the envelope when returning your Request Form. Otherwise, please affix an appropriate stamp. You may also send an email with a scanned copy of the Request Form to everestmedicines.ecom@computershare.com.hk. The Request Form may also be downloaded from the Company’s website at www.everestmedicines.com or the website of HKEx at www.hkexnews.hk.

Should you have any questions in relation to this letter, please call the telephone hotline of the Hong Kong Share Registrar at (852) 2862 8688 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday, excluding Hong Kong public holidays.

Yours faithfully,
By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Note: This letter is addressed to non-registered holders of the Company (a “non-registered holder” means such person or company whose shares in the Company are held in the Central Clearing and Settlement System (CCASS) and who has notified the Company from time to time through Hong Kong Securities Clearing Company Limited that such person or company wishes to receive Corporate Communications[#]). If you have sold or transferred all your shares in the Company, please disregard this letter and the Request Form on the reverse side.

Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and financial statements contained in them), notices of meetings, listing documents, circulars and proxy forms.

各位非登記持有人^(#)：

雲頂新耀有限公司（「公司」）

- 2023 年度報告及 2023 年度環境、社會及管治報告（「本次公司通訊」）之發佈通知

本次公司通訊之中、英文版本已上載於公司網站(www.everestmedicines.com)及香港交易及結算所有限公司（「香港交易所」）網站(www.hkexnews.hk)，歡迎查閱。

如閣下欲收取本次公司通訊之印刷本及所有日後公司通訊[#]，請閣下填妥在本函背面的申請表格，並在申請表格上簽名，然後把申請表格寄回或親手交回香港中央證券登記有限公司（「香港證券登記處」），地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。倘若閣下在香港投寄，可使用申請表格內的郵寄標籤寄回，而毋須在信封上貼上郵票；否則，請貼上適當的郵票。閣下亦可把已填妥之申請表格的掃描副本電郵至 everestmedicines.ecom@computershare.com.hk。申請表格亦可於公司網站(www.everestmedicines.com)或香港交易所網站(www.hkexnews.hk)內下載。

閣下如有任何與本函內容有關的疑問，請致電香港證券登記處電話熱線(852) 2862 8688，辦公時間為星期一至星期五（香港公眾假期除外）上午 9 時正至下午 6 時正。

承董事會命
雲頂新耀有限公司
主席兼執行董事
傅唯
謹啟

2024 年 4 月 25 日

附註：本函件乃向本公司之非登記持有人（「非登記持有人」指本公司股份存放於中央結算及交收系統的人士或公司，透過香港中央結算有限公司不時向本公司發出通知表示該等人士或公司希望收到公司通訊[#]）發出。倘若閣下已出售或轉讓所持有的所有本公司股份，則無需理會本函及所附申請表格。

公司通訊乃本公司向其證券持有人發出以供參照或採取行動的任何文件，包括但不限於年度和中期財務報告及其摘要報告（及其中包含的所有報告及財務報表）、會議通告、上市文件、通函及委任代表表格。



Name(s) and address of Non-registered holder(s)
非登記持有人之姓名及地址:

Request Form 申請表格

To: Everest Medicines Limited (the "Company")
(Stock Code: 1952)
c/o Computershare Hong Kong Investor Services Limited
17M Floor, Hopewell Centre, 183 Queen's Road East,
Wan Chai, Hong Kong

致: 雲頂新耀有限公司 (「公司」)
(股份代號: 1952)
經香港中央證券登記有限公司
香港灣仔皇后大道東 183 號
合和中心 17M 樓

I/We would like to receive corporate communications[#] from the Company in the manner indicated below:

本人/我們欲以下列方式收取本公司之公司通訊[#] (「公司通訊」):

(Please mark "X" in ONLY ONE of the following boxes)

(請從下列選擇中, 僅在其中一個空格內劃上「X」號)

to receive all Corporate Communications in electronic form on the Company's website at www.everestmedicines.com instead of receiving printed copies, and to receive a printed notification letter for the publication of the relevant Corporate Communications on the website of the Company by post; OR
透過本公司網站 www.everestmedicines.com 收取所有的公司通訊電子本以代替收取印刷本, 並以郵寄方式收取公司通訊文件已在網上刊發之通知信函印刷本; 或

to receive the printed English version of all Corporate Communications by post ONLY; OR
僅以郵寄方式收取所有公司通訊文件之英文印刷本; 或

to receive the printed Chinese version of all Corporate Communications by post ONLY; OR
僅以郵寄方式收取所有公司通訊文件之中文印刷本; 或

to receive both the printed English and Chinese versions of all Corporate Communications by post.
以郵寄方式同時收取所有公司通訊文件之英文及中文印刷本。

Signature(s)
簽署

Contact Phone Number
聯絡電話號碼

Date
日期

Notes 附註:

- This letter is addressed to the non-registered shareholders whose shares are held in The Central Clearing and Settlement System (CCASS) and who have notified the Company from time to time through Hong Kong Securities Clearing Company Limited that they wish to receive Corporate Communications of the Company.
本函件乃向非登記股東發出, 該等人士的股份存放於中央結算及交收系統, 而他們已經透過香港中央結算有限公司不時通知本公司, 希望收取本公司公司通訊。
- Any form with more than one box marked "X", with no box marked "X", with no signature or otherwise incorrectly completed will be void.
如在本表格作出超過一項選擇、或未有作出選擇、或未有簽署、或在其他方面填寫不正確, 則本表格將會作廢。
- The above instruction will apply to the Corporate Communications to be sent to you until you notify to the Company c/o Computershare Hong Kong Investor Services Limited to the contrary or unless you have at anytime ceased to have holdings in the Company.
上述指示適用於發送予閣下之公司通訊, 直至閣下經香港中央證券登記有限公司通知本公司另作安排或除非閣下任何時候停止持有本公司的股份。
- For the avoidance of doubt, we do not accept any special instructions written on this Request Form.
為免存疑, 任何在本申請表格上額外手寫的指示, 本公司將不予處理。

Corporate communications are all documents issued by the Company to holders of its securities for their information or action and include (but are not limited to) full and summary annual and interim financial reports (and all reports and financial statements contained in them), notices of meetings, listing documents, circulars and proxy forms.
公司通訊乃本公司向其證券持有人發出以供參照或採取行動的任何文件, 包括但不限於年度和中期財務報告及其摘要報告 (及其中包含的所有報告及財務報表)、會議通告、上市文件、通函及委任代表表格。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited
香港中央證券登記有限公司

Freepost No. 簡便回郵號碼: 37
Hong Kong 香港

Please cut the mailing label and stick it on an envelope
to return this Request Form to us.

No postage is necessary if posted in Hong Kong.

閣下寄回本申請表格時, 請將郵寄標籤剪貼於信封上。
如在本港投寄, 閣下無需支付郵費或貼上郵票。

Get in touch with us 與我們聯繫

Send us an enquiry 垂詢
Rate our service 評價
Lodge a complaint 投訴



Contact Us 聯繫我們

www.computershare.com/hk/contact